

Statutory Auditor resignation

Milan (Italy), May 25th 2020 –MolMed S.p.A. (MLMD.MI) (“**MolMed**” or the “**Company**”) informs that Mrs. Flavia Daunia Minutillo resigned from the office of member of the Company's Board of Statutory Auditors, with effect at the end of today, due to new arisen reasons related to cumulation of positions held. Mrs. Flavia Daunia Minutillo declared that, as of today, she does not own any shareholding in MolMed.

Pursuant to the combined provisions of Article 2401 of the Italian Civil Code and Article 23 of the Company's By-laws, the office of Statutory Auditor shall be taken, with effect as of today and until the next Shareholders' Meeting, by the Alternate Auditor Mrs. Alessia Bastiani, whose name was selected from the same List submitted by the Company's shareholder Finanziaria d'investimento Fininvest S.p.A., where Flavia Daunia Minutillo was nominated by the Shareholders' Meeting held on 30th April 2019.

Mrs. Alessia Bastiani's *curriculum vitae*, which was made available to the public on the occasion of Shareholders' Meeting held on 30th April 2019 for the appointment of the whole Board of Statutory Auditors, is currently available on the Company's website in the Section Investor relation/Shareholders' meetings/ Shareholders' meetings/ held on 30th April 2019.

Mrs. Alessia Bastiani confirmed the declarations required by law, previously rendered on occasion of her appointment as Alternate Auditor and declared that, as of today, she does not own any shareholding in MolMed.

MolMed thanks Mrs. Flavia Daunia Minutillo for the precious contribution she has given to the Company in her term.

About MolMed

MolMed S.p.A. is a clinical stage biotech company focused on research, development, manufacturing and clinical validation of innovative therapies. MolMed is the first company in Europe to have obtained the GMP manufacturing authorization for cell & gene therapies *ex vivo* for its proprietary products as well as for third parties and/or in partnership (Strimvelis, an Orchard gene therapy for the ADA-SCID). With reference to GMP development and manufacturing activities for third parties, MolMed signed numerous partnership agreements with leading European and US companies. MolMed's is also developing its CAR-T CD44v6, which in March 2019 received the authorization to start human clinical trials in onco-hematologic indications (AML and MM), following an extensive pre-clinical phase. MolMed, founded in 1996 as an academic spin-off of the San Raffaele Scientific Institute, is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana since March 2008. MolMed is headquartered and based in Milan, at the San Raffaele Biotechnology Department (DIBIT) and has an operating unit at OpenZone in Bresso. For more information please visit www.molmed.com.



PRESS RELEASE

For further information:

MolMed S.p.A.

Investor Relations & Communication Department

MolMed S.p.A.

+39 02 21277.205

investor.relations@molmed.com

Tommasina Cazzato

Press Office

Community Group

+39 345 7357751

tommasina.cazzato@communitygroup.it